Cargando…

WHSC1/NSD2 regulates immune infiltration in prostate cancer

BACKGROUND: Immunotherapy in prostate cancer (PCa) lags behind the progresses obtained in other cancer types partially because of its limited immune infiltration. Tumor-resident immune cells have been detected in the prostate, but the regulatory mechanisms that govern tumor infiltration are still po...

Descripción completa

Detalles Bibliográficos
Autores principales: Want, Muzamil Y, Tsuji, Takemasa, Singh, Prashant K, Thorne, James L, Matsuzaki, Junko, Karasik, Ellen, Gillard, Bryan, Cortes Gomez, Eduardo, Koya, Richard C., Lugade, Amit, Odunsi, Kunle, Battaglia, Sebastiano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7887377/
https://www.ncbi.nlm.nih.gov/pubmed/33589522
http://dx.doi.org/10.1136/jitc-2020-001374
_version_ 1783651969890516992
author Want, Muzamil Y
Tsuji, Takemasa
Singh, Prashant K
Thorne, James L
Matsuzaki, Junko
Karasik, Ellen
Gillard, Bryan
Cortes Gomez, Eduardo
Koya, Richard C.
Lugade, Amit
Odunsi, Kunle
Battaglia, Sebastiano
author_facet Want, Muzamil Y
Tsuji, Takemasa
Singh, Prashant K
Thorne, James L
Matsuzaki, Junko
Karasik, Ellen
Gillard, Bryan
Cortes Gomez, Eduardo
Koya, Richard C.
Lugade, Amit
Odunsi, Kunle
Battaglia, Sebastiano
author_sort Want, Muzamil Y
collection PubMed
description BACKGROUND: Immunotherapy in prostate cancer (PCa) lags behind the progresses obtained in other cancer types partially because of its limited immune infiltration. Tumor-resident immune cells have been detected in the prostate, but the regulatory mechanisms that govern tumor infiltration are still poorly understood. To address this gap, we investigated the role of Wolf-Hirschhorn syndrome candidate 1 (WHSC1), a histone methyltransferase enzyme that targets dimethyl and trimethyl H3K36. WHSC1 is known to promote malignant growth and progression in multiple tumors, but its role in the interface between PCa and immune system is unknown. METHODS: RNA Sequencing (RNASeq) data from patients with PCa from The Cancer Genome Atlas (TCGA) were collected and divided into top/bottom 30% based on the expression of WHSC1 and disease-free survival was calculated. Publicly available chromatin immunoprecipitation (ChIPSeq) data were obtained from Cistrome and integrated with the available RNASeq data. RNASeq, ATACSeq and methylomic were analyzed using R Bioconductor packages comparing C42 cells with or without stable knockdown on WHSC1. Flow cytometry was used to measure Major Histocompatibility complex (MHC) levels, MHC-bound ovalbumin and tumor infiltration. C57B6 and NOD scid gamma (NSG) mice were subcutaneously grafted with TRansgenic Adenocarcinoma of the Mouse Prostate (TRAMP) C2 cells and treated with MCTP39 (10 mg/kg); tumor size was monitored over time and curves were compared using permutation analyses. All analyses used a significance threshold of 0.05. RESULTS: Leveraging TCGA data, we demonstrated that elevated WHSC1 levels positively correlate with the presence of an immunosuppressive microenvironment. We validated those results in vitro, demonstrating that genetic and pharmacological inhibition of WHSC1 restores antigen presentation. This occurs via an elegant epigenetic regulation of gene expression at the chromatin and DNA methylation levels. In vivo studies in immunocompetent mice also show an increased frequency of CD8(+) T cells in tumors from mice treated with WHSC1 inhibitor, supporting the hypothesis that the antitumor effect following WHSC1 inhibition requires a fully functional immune system. CONCLUSIONS: This study demonstrates a novel role for WHSC1 in defining immune infiltration in PCa, with significant future implications for the use of immunotherapies in prostate malignancies.
format Online
Article
Text
id pubmed-7887377
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-78873772021-03-03 WHSC1/NSD2 regulates immune infiltration in prostate cancer Want, Muzamil Y Tsuji, Takemasa Singh, Prashant K Thorne, James L Matsuzaki, Junko Karasik, Ellen Gillard, Bryan Cortes Gomez, Eduardo Koya, Richard C. Lugade, Amit Odunsi, Kunle Battaglia, Sebastiano J Immunother Cancer Clinical/Translational Cancer Immunotherapy BACKGROUND: Immunotherapy in prostate cancer (PCa) lags behind the progresses obtained in other cancer types partially because of its limited immune infiltration. Tumor-resident immune cells have been detected in the prostate, but the regulatory mechanisms that govern tumor infiltration are still poorly understood. To address this gap, we investigated the role of Wolf-Hirschhorn syndrome candidate 1 (WHSC1), a histone methyltransferase enzyme that targets dimethyl and trimethyl H3K36. WHSC1 is known to promote malignant growth and progression in multiple tumors, but its role in the interface between PCa and immune system is unknown. METHODS: RNA Sequencing (RNASeq) data from patients with PCa from The Cancer Genome Atlas (TCGA) were collected and divided into top/bottom 30% based on the expression of WHSC1 and disease-free survival was calculated. Publicly available chromatin immunoprecipitation (ChIPSeq) data were obtained from Cistrome and integrated with the available RNASeq data. RNASeq, ATACSeq and methylomic were analyzed using R Bioconductor packages comparing C42 cells with or without stable knockdown on WHSC1. Flow cytometry was used to measure Major Histocompatibility complex (MHC) levels, MHC-bound ovalbumin and tumor infiltration. C57B6 and NOD scid gamma (NSG) mice were subcutaneously grafted with TRansgenic Adenocarcinoma of the Mouse Prostate (TRAMP) C2 cells and treated with MCTP39 (10 mg/kg); tumor size was monitored over time and curves were compared using permutation analyses. All analyses used a significance threshold of 0.05. RESULTS: Leveraging TCGA data, we demonstrated that elevated WHSC1 levels positively correlate with the presence of an immunosuppressive microenvironment. We validated those results in vitro, demonstrating that genetic and pharmacological inhibition of WHSC1 restores antigen presentation. This occurs via an elegant epigenetic regulation of gene expression at the chromatin and DNA methylation levels. In vivo studies in immunocompetent mice also show an increased frequency of CD8(+) T cells in tumors from mice treated with WHSC1 inhibitor, supporting the hypothesis that the antitumor effect following WHSC1 inhibition requires a fully functional immune system. CONCLUSIONS: This study demonstrates a novel role for WHSC1 in defining immune infiltration in PCa, with significant future implications for the use of immunotherapies in prostate malignancies. BMJ Publishing Group 2021-02-15 /pmc/articles/PMC7887377/ /pubmed/33589522 http://dx.doi.org/10.1136/jitc-2020-001374 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Clinical/Translational Cancer Immunotherapy
Want, Muzamil Y
Tsuji, Takemasa
Singh, Prashant K
Thorne, James L
Matsuzaki, Junko
Karasik, Ellen
Gillard, Bryan
Cortes Gomez, Eduardo
Koya, Richard C.
Lugade, Amit
Odunsi, Kunle
Battaglia, Sebastiano
WHSC1/NSD2 regulates immune infiltration in prostate cancer
title WHSC1/NSD2 regulates immune infiltration in prostate cancer
title_full WHSC1/NSD2 regulates immune infiltration in prostate cancer
title_fullStr WHSC1/NSD2 regulates immune infiltration in prostate cancer
title_full_unstemmed WHSC1/NSD2 regulates immune infiltration in prostate cancer
title_short WHSC1/NSD2 regulates immune infiltration in prostate cancer
title_sort whsc1/nsd2 regulates immune infiltration in prostate cancer
topic Clinical/Translational Cancer Immunotherapy
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7887377/
https://www.ncbi.nlm.nih.gov/pubmed/33589522
http://dx.doi.org/10.1136/jitc-2020-001374
work_keys_str_mv AT wantmuzamily whsc1nsd2regulatesimmuneinfiltrationinprostatecancer
AT tsujitakemasa whsc1nsd2regulatesimmuneinfiltrationinprostatecancer
AT singhprashantk whsc1nsd2regulatesimmuneinfiltrationinprostatecancer
AT thornejamesl whsc1nsd2regulatesimmuneinfiltrationinprostatecancer
AT matsuzakijunko whsc1nsd2regulatesimmuneinfiltrationinprostatecancer
AT karasikellen whsc1nsd2regulatesimmuneinfiltrationinprostatecancer
AT gillardbryan whsc1nsd2regulatesimmuneinfiltrationinprostatecancer
AT cortesgomezeduardo whsc1nsd2regulatesimmuneinfiltrationinprostatecancer
AT koyarichardc whsc1nsd2regulatesimmuneinfiltrationinprostatecancer
AT lugadeamit whsc1nsd2regulatesimmuneinfiltrationinprostatecancer
AT odunsikunle whsc1nsd2regulatesimmuneinfiltrationinprostatecancer
AT battagliasebastiano whsc1nsd2regulatesimmuneinfiltrationinprostatecancer